Infosec, Manufacturing

UPDATED: House committee wants to know a lot more about the cyberattack that damaged Merck

Forecasts

AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs

Results

UPDATED: Two years on, Allergan’s $1.7B NASH drug still looks weak — at best
More news caret

calendar Protocols

Quick hits from around the biopharma web

Sep 22

AbbVie partners on an Opdivo combo study with Bristol-Myers; Intercept tumbles on FDA warning

Sep 20

Arcus scores $305M regional development pact with Taiho; Shire, Shionogi tout PhIII ADHD study

Sep 19

OptiNose files for $100M IPO; GSK wins three-in-one COPD OK

Sep 18

Avanir vet Keith Katkin takes charge at Urovant; Teva unloads assets while uploading new CEO

More Protocols caret

thumbthumb Thumbs Up/Down

Jun 16

From bombs to bromides? Trump’s jousting with biopharma may well boil down to a handshake on drug prices

Jun 9

8 stars: A look back at ASCO spotlights the top cancer drugs to watch, and 1 to forget

Jun 2

Thumbs up: Cancer drug R&D is exploding, get ready for the pricing debate to follow

May 26

Some worthy initiatives out of the FDA fall far short of an effective federal plan to rein in drug prices

More Thumbs Up/Downcaret

DNA Deep dives

Optimizing clinical outcomes for challenging molecules with lipid-based drug delivery

What’s a biotech CEO worth? The top 15 pay packages puts a spotlight on performance — usually

A biotech billionaire tops the list of the 15 highest paid R&D execs in biopharma

The top 15 spenders in the global drug R&D business: 2017

Planning a clinical supply program? Don’t overlook primary packaging.

Alzheimer’s: Learning From a Legacy of Bitter Setbacks

twitter Marco

Hot BioTwitter bot - last updated ago

arrow-thick Most Viral

Novartis's $475,000 Price Tag on Cancer Drug Meets Resistance

Bloomberg John Lauerman a day

Gene Therapy Is Nearing a Major Breakthrough

Barron's Andrew Bary a day

McCain Announces Opposition to Republican Health Bill, Likely Dooming Its Fate

New York Times Thomas Kaplan a day

House committee wants to know a lot more about the cyberattack that damaged Merck

ENDPOINTS NEWS Arsalan Arif a day

Medicaid directors issue warning on new ObamaCare repeal bill

TheHill a day

If the U.S. Adopts the G.O.P.'s Health-Care Bill, It Would Be an Act of Mass Suicide

The New Yorker The New Yorker a day

Criminal and civil actions filed against Aegerion Pharmaceuticals Inc.

FDA a day

To advance precision medicine, NIH turns to long-mistreated communities

STAT a day

New antibody attacks 99% of HIV strains

BBC News a day

The HPV Vaccine Gains Ground Among U.S. Teenagers

New York Times Aneri Pattani a day

timer Latest

Forbes

Ten Annoying Things People Do At Work -- And How To Make Them Stop

Forbes

New Scans Reveal What Lies Beneath Venice's Canals

WSJ

Puerto Rico's Mayors Tell of Devastation From Hurricane Maria

U.S. Department of Justice

United States of America v. Aegerion Pharmaceuticals, Inc. and Dr. Charles M. Gerrits

Bristol-Myers Squibb

Bristol-Myers Squibb's Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib

U.S.

U.S. FDA declines to approve J&J arthritis drug

OncLive

FDA Approves Pembrolizumab for PD-L1+ Gastric Cancer

BioCentury

Tribe files to dismiss Restasis patent IPR cases

Barron's

Gene Therapy Is Nearing a Major Breakthrough

ENDPOINTS NEWS

FDA spurns J&J's troubled rheumatoid arthritis drug sirukumab

fire Hot This Week

1

Bloomberg

FDA Clears Biotech Drug Copycats, But Buying Them Isn't So Easy

2

STAT

Alnylam hits all key endpoints in crucial trial of rare disease drug

3

WSJ

The Murky World of Drug Rebates Gets Airing in Lawsuit

4

ENDPOINTS NEWS

Alnylam achieves breakthrough RNAi success as PhIII patisiran study hits all goals

5

STAT

Here's why Alnylam stock took off like a rocket, stunning investors

6

STAT

The Biotech Devil's Dictionary: Your guide to the inanities of industry jargon

7

STAT

In excruciating pain, sickle cell patients are shunted aside

8

Vox

"I've covered the GOP repeal plans since day one. Graham-Cassidy is the most radical."

9

MIT Technology Review

Prospect of synthetic embryos sparks new bioethics debate

10

ENDPOINTS NEWS

Atlas ramps up a new biotech player focused on neurology, with a $30M round to fund the work

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back